p53 as a hub in cellular redox regulation and therapeutic target in cancer
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
The TP53 tumor suppressor gene encodes a DNA-binding transcription factor that regulates multiple cellular processes including cell growth and cell death. The ability of p53 to bind to DNA and activate transcription is tightly regulated by post-translational modifications and is dependent on a reducing cellular environment. Some p53 transcriptional target genes are involved in regulation of the cellular redox homeostasis, e.g. TIGAR and GLS2. A large fraction of human tumors carry TP53 mutations, most commonly missense mutations that lead to single amino acid substitutions in the core domain. Mutant p53 proteins can acquire so called gain-of-function activities and influence the cellular redox balance in various ways, for instance by binding of the Nrf2 transcription factor, a major regulator of cellular redox state. The DNA-binding core domain of p53 has 10 cysteine residues, three of which participate in holding a zinc atom that is critical for p53 structure and function. Several novel compounds that refold and reactivate missense mutant p53 bind to specific p53 cysteine residues. These compounds can also react with other thiols and target components of the cellular redox system, such as glutathione. Dual targeting of mutant p53 and redox homeostasis may allow more efficient treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is established that transcription factor p53 is the master regulator of the DNA damage response and is stabilized and transactivated in response to DNA damage [ 38 , 39 , 40 , 41 ].”
From Differential Induction of Reactive Oxygen Species and Expression of Antioxidant Enzymes in Human Melanocytes Correlate with Melanin Content: Implications on the Response to Solar UV and Melanoma Susceptibility (2022) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MicroRNA-124 Regulates the Proliferation of Colorectal Cancer Cells by TargetingiASPP
Liu, K., Zhao, H., Yao, H., Lei, S., Lei, Z., Li, T., & Qi, H. (2013) · BioMed Research International · doi:10.1155/2013/867537 · Cited by 60
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 16×
“FDXR is a mitochondrial protein involved in iron–sulfur cluster formation and the transfer of electrons from NADPH to cytochrome P450 enzymes.”
BackgroundInfluentialFree radicals, metals and antioxidants in oxidative stress-induced cancer
Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., & Mazur, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.12.009 · Cited by 6,680 · cited 1×
“Counteracting oxidative stress in order to maintain a reduced environment is essential as accumulation of oxygen species is harmful to the cell and can initiate cancer (Valko et al., 2006).”
BackgroundMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · cited 2×
“Thus, their redox balance is already pushed to the limit, and a further increase in oxidant species may therefore tip them over the edge and trigger cell death (Gorrini et al., 2013).”
BackgroundFerroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 11×
“As SLC7A11 controls both cystine/cysteine redox cycling and the availability GSH building blocks, the repression of SLC7A11 renders mutant p53 cells more sensitive to oxidative assaults.”
BackgroundInfluentialBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Also, p53 has continued to fascinate and surprise investigators through its involvement in a wide range of diverse cellular processes (Vousden and Prives, 2009), and by the discovery of multiple p53 isoforms with as yet poorly understood functions (Marcel et al.”
BackgroundWendel, A. (1981) · Methods in Enzymology · doi:10.1016/s0076-6879(81)77046-0 · Cited by 3,009
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Thus, as mutant p53 prolongs TNF-α-induced NFκB signaling (Cooks et al., 2013), it is conceivable that mutant p53 can upregulate Nrf2 via NFκB.”
Background
Cited by
Targeting ROS in cancer: rationale and strategies
Glorieux, C., Liu, S., Trachootham, D., & Huang, P. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00979-4 · Cited by 651
“By contrast, BCL-2, a mitochondrial membrane-associated protein, exerts its non-canonical antioxidant function to help maintain redox homeostasis. c , ROS generated in the tumour microenvironment through various mechanisms, including aberrant metabolism due to dysfunctional mitochondria, toll-like receptor (TLR) activ…”
InfluentialLacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
DNA damage and oxidant stress activate p53 through differential upstream signaling pathways
Shi, T., van Soest, D. M. K., Polderman, P. E., Burgering, B. M. T., & Dansen, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.06.013 · Cited by 172
Roles of reactive oxygen species in inflammation and cancer
Yu, Y., Liu, S., Yang, L., Song, P., Liu, Z., Liu, X., Yan, X., & Dong, Q. (2024) · MedComm · doi:10.1002/mco2.519 · Cited by 164
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases
Shadfar, S., Parakh, S., Jamali, M. S., & Atkin, J. D. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00350-4 · Cited by 158
“Moreover, p53 is regulated by redox signalling, thus it has been referred to as a central ‘hub’ in redox homeostasis [208] because it also mediates antioxidant and pro-oxidant pathways [208].”
BackgroundBoullosa, L. F., Loenhout, J. V., Flieswasser, T., Waele, J. D., Hermans, C., Lambrechts, H. A. J., Cuypers, B., Laukens, K., Bartholomeus, E., Siozopoulou, V., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101949 · Cited by 126
“Trx and TrxR are major proteins taking part in the regulation of many transcription factors, including p53, and thus the redox state of cells [60, 61].”
BackgroundNADPH-dependent and -independent disulfide reductase systems
Miller, C. G., Holmgren, A., Arnér, E. S. J., & Schmidt, E. E. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.03.051 · Cited by 118
Molecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 114
Cheteh, E. H., Sarne, V., Ceder, S., Bianchi, J., Augsten, M., Rundqvist, H., Egevad, L., Östman, A., & Wiman, K. G. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0272-5 · Cited by 104
Self-citationZinc: Multidimensional Effects on Living Organisms
Cuajungco, M. P., Ramirez, M. S., & Tolmasky, M. E. (2021) · Biomedicines · doi:10.3390/biomedicines9020208 · Cited by 116
“proteins illustrates its fundamental role in numerous biological processes [7-12].”
BackgroundG6PD: A hub for metabolic reprogramming and redox signaling in cancer
Yang, H., Stern, A., & Chiu, D. T.-Y. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.08.001 · Cited by 101
“[45] Eriksson SE, Ceder S, Bykov VJN, Wiman KG.”
BackgroundGlutaminases regulate glutathione and oxidative stress in cancer
Matés, J. M., Campos-Sandoval, J. A., de los Santos-Jiménez, J., & Márquez, J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02838-8 · Cited by 91
“, TIGAR, GLS2, SESN1/2, and p21-dependent activation of NRF2 (Eriksson et al. 2019; Kitano et al. 2018).”
BackgroundInfluentialGender Differences in Oxidative Stress in Relation to Cancer Susceptibility and Survival
Allegra, A., Caserta, S., Genovese, S., Pioggia, G., & Gangemi, S. (2023) · Antioxidants · doi:10.3390/antiox12061255 · Cited by 76
“As a result, an increase in ROS promotes the accumulation of p53, because p53 is tightly tied to redox processes [62].”
BackgroundWang, Z., Yu, K., Hu, Y., Su, F., Gao, Z., Hu, T., Yang, Y., Cao, X., & Qian, F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113673 · Cited by 68
Targeting Redox Metabolism in Pancreatic Cancer
Hadi, N. A., Reyes‐Castellanos, G., & Carrier, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041534 · Cited by 68
“In addition, mutant p53 proteins can acquire so-called gain-of-function activities and influence the cellular redox balance in various ways, for instance by binding to the Nrf2 transcription factor, a major regulator of cellular redox state as discussed above [76].”
BackgroundThe p53/MDM2/MDMX-targeted therapies – a clinical synopsis
Jiang, L., & Zawacka-Pankau, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2445-9 · Cited by 62
The p53 Pathway and Metabolism: The Tree That Hides the Forest
Lahalle, A., Lacroix, M., Blasio, C. D., Cissé, M. Y., Linares, L. K., & Cam, L. L. (2021) · Cancers · doi:10.3390/cancers13010133 · Cited by 76
“Nevertheless, several studies have shown that its DNA binding properties are directly controlled by intracellular ROS, heme, or ceramide levels, supporting the notion that p53 is also a bona fide metabolic sensor [66,95,96].”
BackgroundProtein persulfidation: Rewiring the hydrogen sulfide signaling in cell stress response
He, B., Zhang, Z., Huang, Z., Duan, X., Wang, Y., Cao, J., Li, L., He, K., Nice, E. C., He, W., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115444 · Cited by 62
Thioredoxin Signaling Pathways in Cancer
Zhang, J., Li, X., Zhao, Z., Cai, W., & Fang, J. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0074 · Cited by 73
“The ability of p53 to bind to DNA and activate transcription is tightly regulated by post-translational modifications, and is dependent on the reducing cellular environment (Eriksson et al, 2019).”
Lan, T., Arastu, S., Lam, J., Kim, H., Wang, W., Wang, S. R., Bhatt, V. D., Lopes, E. C., Hu, Z. S., Sun, M. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50157-8 · Cited by 69
“While ROS are pro-tumorigenic, high ROS levels are cytotoxic 30 and can be induced by oncogenic activity 48 . p53 in fl uences the cellular redox balance by regulating several genes with antioxidant or pro-oxidant properties, which depends on various factors, including p53 protein levels 49 .”
Mutant p53 in cell-cell interactions
Pilley, S., Rodriguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 53
“However, APR-246 and its related compounds also show a variety of p53-independent activities that could underlie therapeutic efficacy (Bykov et al. 2018; Eriksson et al. 2019).”
BackgroundXu, L., Cao, Y., Ya, X., Li, R., & Xu, X. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300238 · Cited by 57
p53 induces ARTS to promote mitochondrial apoptosis
Hao, Q., Chen, J., Liao, J., Huang, Y., Gan, Y., Larisch, S., Zeng, S. X., Lu, H., & Zhou, X. Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03463-8 · Cited by 53
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S., & Crown, J. P. (2022) · Cancers · doi:10.3390/cancers14184499 · Cited by 55
Leu, J. I.-J., Murphy, M. E., & George, D. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009943117 · Cited by 47
Targeting Mitochondrial Metabolic Reprogramming as a Potential Approach for Cancer Therapy
Zhang, L., Wei, Y., Yuan, S., & Sun, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054954 · Cited by 55
“In addition, p53 can also induce mitochondrial GLS2 expression to enhance GSH synthesis and α-KG, thus promoting the TCA cycle [49].”
BackgroundHarnessing altered oxidative metabolism in cancer by augmented prooxidant therapy
Firczuk, M., Bajor, M., Graczyk‐Jarzynka, A., Fidyt, K., Góral, A., & Zagożdżon, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.037 · Cited by 46
Gencheva, R., Cheng, Q., & Arnér, E. S. J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.020 · Cited by 54
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41
“…that APR-246 treatment leads to an increased xCT protein level in tumor cells (Ali et al, 2016; Liu et al, 2017; Lisek et al, 2018; Synnott et al, 2018), possibly due to its inhibition of mutant p53-NRF2 complexing and/or its pro-oxidant activities (Walerych et al, 2016; Eriksson et al, 2019).”
BackgroundMethodInfluentialSelf-citationHumpton, T. J., Hall, H., Kiourtis, C., Nixon, C., Clark, W. A., Hedley, A., Shaw, R., Bird, T. G., Blyth, K., & Vousden, K. H. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00871-3 · Cited by 47
“Considering the established role for p53 supporting the redox response [36], we investigated whether the disrupted lipid clearance in Albumin-Cre; p53 mice was a consequence of decreased ROS detoxification.”
BackgroundCurrent Progress of Ferroptosis Study in Hepatocellular Carcinoma
Zhu, X., Sha, X., Zang, Y., Ren, Q., Zhang, S., Ma, D., Wang, L., Yao, J., Zhou, X. Y., Yu, L., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.96014 · Cited by 43
“Remarkably, numerous studies have provided evidence that p53, a hub involved in cellular redox regulation and a therapeutic target in cancer, has various effects on ferroptotic cell death [97].”
BackgroundZinc Deficiency Promotes Testicular Cell Apoptosis in Mice
Chen, Y., Yang, J., Wang, Y., Yang, M., & Guo, M. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01821-4 · Cited by 39
“Under normal circumstances, the two forces of pro-survival (Bcl-2, Bcl-XL, and Bcl-W) and pro-apoptosis (Bax, Bad, Bcl-Xs, Bak, and Bid) are evenly matched [15].”
The dual role of p62 in ferroptosis of glioblastoma according to p53 status
Yuan, F., Sun, Q., Zhang, S., Ye, L., Xu, Y., Deng, G., Xu, Z., Zhang, S., Liu, B., & Chen, Q. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00764-z · Cited by 43
“Some scientists believe that while low levels of p53 can induce NRF2, conditions that lead to high p53 protein levels seem to compromise NRF2 activity [39].”
BackgroundTP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
Cumbo, C., Tota, G., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103432 · Cited by 41
“MQ not only reactivates mutant p53, but also targets antioxidant molecules influencing the cellular redox balance [149].”
BackgroundMore than Just Antioxidants: Redox-Active Components and Mechanisms Shaping Redox Signalling Network
Kuczyńska, M., Jakubek, P., & Bartoszek, A. (2022) · Antioxidants · doi:10.3390/antiox11122403 · Cited by 41
“Another reason for the popularity of p53 among res archers is the frequent mutations of the TP53 gene observed in uman cancers and t e presence of many is forms of this protei , often with still poorly understood functions [99].”
Backgroundp53 at the crossroad between mitochondrial reactive oxygen species and necroptosis
Rius‐Pérez, S. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.022 · Cited by 40
Fetoni, A. R., Paciello, F., & Troiani, D. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0183 · Cited by 39
“Mutant p53 proteins can be produced in response to inflammation and oxidative stress, facilitating cancer cell proliferation, chemoresistance, and metastasis (53, 124).”
Upadhyay, P. R., Starner, R. J., Swope, V. B., Wakamatsu, K., Ito, S., & Abdel-Malek, Z. A. (2022) · Antioxidants · doi:10.3390/antiox11061204 · Cited by 30
Korgaonkar, N., & Yadav, K. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117060 · Cited by 32
The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19
Emanuele, S., Celesia, A., D’Anneo, A., Lauricella, M., Carlisi, D., Blasio, A. D., & Giuliano, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157963 · Cited by 31
“I triguingly, low levels of 53 seem to promote the expression of genes with antioxid t functions, whereas higher p53 levels, resulting from considerable stress conditions, induce pro-oxidant and pro-apoptotic arget genes [30].”
BackgroundNovel insight into the Warburg effect: Sweet temptation
Zhang, H., Liu, S., Fu, S., Zhao, Q., Wang, Y., Yuan, Y., & Zhang, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104844 · Cited by 37
Jia, J., Zhai, S., Cai, T., Guo, P., Yang, G., Chang, Z., Chen, Y., Song, X., Lu, X., Chu, L., et al. (2026) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250908 · Cited by 27
Addison, R., Weatherhead, S. C., Pawitri, A., Smith, G. R., Rider, A., Grantham, H. J., Cockell, S., & Reynolds, N. J. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101924 · Cited by 29
“protein, induced by p53, stabilizes the master antioxidant regulator NRF2, with the potential for further feedback loops as NRF2 itself induces CDKN1A, SESN2 and MDM2 [8].”
BackgroundInfluentialNanoparticles (NPs)-mediated targeted regulation of redox homeostasis for effective cancer therapy
Zhao, Z., Cao, Y., Xu, R. F., Fang, J., Zhang, Y., Xu, X., Huang, L., & Li, R. (2024) · Smart Materials in Medicine · doi:10.1016/j.smaim.2024.03.003 · Cited by 30
Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
Butturini, E., Butera, G., Pacchiana, R., de Prati, A. C., Mariotto, S., & Donadelli, M. (2021) · Cells · doi:10.3390/cells10113149 · Cited by 28
“From a therapeutic perspective, p53 cysteine residues are important targets of novel compounds that refold missense mutant p53 binding to specific p53 cysteine residues [6].”
BackgroundIschemia–Reperfusion Injury: Molecular Mechanisms of Pathogenesis and Methods of Their Correction
Goncharov, R. G., & Sharapov, M. G. (2023) · Molecular Biology · doi:10.1134/s0026893323060067 · Cited by 25
The Role of Reductive Stress in the Pathogenesis of Endocrine-Related Metabolic Diseases and Cancer
Mladenov, M. I., Sazdova, I., Hadzi‐Petrushev, N., Konakchieva, R., & Gagov, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051910 · Cited by 25
“Beyond these canonical functions, p53 plays a pivotal role in redox balance by modulating the expression of antioxidant genes, including GPx and sestrins [144–146].”
Oxidative stress and gender disparity in cancer
Kim, S. Y. (2022) · Free Radical Research · doi:10.1080/10715762.2022.2038789 · Cited by 27
“However, abnormally overproduced ROS have very detrimental effects on cells, such as damage of RNA or DNA, lipids peroxidation, oxidation of amino acids in proteins, and loss of activity of the specific enzymes, and cause a variety of diseases [21].”
BackgroundAnticancer Therapeutic Strategies Targeting p53 Aggregation
Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911023 · Cited by 24
Kim, E. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5758 · Cited by 32
“Mutated p53 often forms aggregates and is associ‑ ated with loss of function (LOF), dominant‑negative and gain‑of‑function (GOF) mutations at hotspot regions (120,121).”
The iron–sulphur cluster in human DNA2 is required for all biochemical activities of DNA2
Mariotti, L., Wild, S., Brunoldi, G., Piceni, A., Ceppi, I., Kummer, S., Lutz, R. E., Ćejka, P., & Gari, K. (2020) · Communications Biology · doi:10.1038/s42003-020-1048-4 · Cited by 26
Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity
Haupt, S., & Haupt, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.632719 · Cited by 24
“Wt p53 and mitochondria are fundamentally engaged in energy production and stress response, as reviewed in depth (Budanov, 2014; Eriksson et al., 2019).”
BackgroundProtective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
Advani, D., Gupta, R. V., Tripathi, R. S., Sharma, S., Ambasta, R. K., & Kumar, P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104841 · Cited by 25
idpr: A package for profiling and analyzing Intrinsically Disordered Proteins in R
McFadden, W. M., & Yanowitz, J. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266929 · Cited by 21
“Further, p53 has reported roles in redox regulation [42, 65, 66].”
BackgroundResultLyons, N., Giri, R., Begun, J., Clark, D. A., Proud, D. M., He, Y., Hooper, J. D., & Kryza, T. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0127 · Cited by 22
“…maintainace of which is undertaken by the TrxR1-Trx antioxidant system (Jayaraman et al., 1997) and through regulationofessential pathwaysfor redox homeostasis controling GPx1, GLS2, TIGAR, and TP53INP expression (Eriksson et al., 2019) and cell survival through p21 expression (Chen et al., 2012).”
Jamali, F., Lan, K., Daniel, P. M., Petrecca, K., Sabri, S., & Abdulkarim, B. (2024) · Antioxidants · doi:10.3390/antiox13101201 · Cited by 24
“Wild-type (wt) TP53 acts as a redox-sensitive transcription factor involved in cell cycle arrest, apoptosis, DNA repair, and fine-tuned regulation of either antioxidant or pro-oxidant transcriptional targets depending on basal cellular p53 function in a reducing environment [22].”
Emerging role and therapeutic implications of p53 in intervertebral disc degeneration
Wang, Y., Hu, S., Zhang, W., Zhang, B.-F., & Yang, Z. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01730-5 · Cited by 22
“Under physiological and mild stress conditions, p53 exerts its antioxidant activity by activating down-stream antioxidant target genes, including TP53-inducible glycolysis and apoptosis regulator, sestrin 1/2 (SESN1/2), TP53-induced nuclear protein 1, and p21 [301].”
BackgroundWild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
Corazzari, M., & Collavin, L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1148192 · Cited by 23
“Notably, depending on cellular context, p53 can increase NRF2 levels by preventing its degradation, or reduce NRF2 levels by repressing its transcription (Eriksson et al., 2019; Liu and Gu, 2022a).”
BackgroundInfluentialCeder, S., Eriksson, S. E., Liang, Y. Y., Cheteh, E. H., Zhang, S. M., Fujihara, K. M., Bianchi, J., Bykov, V. J. N., Abrahmsen, L., Clemons, N. J., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03988-y · Cited by 18
“Antiporter xCT is regulated by master antioxidant sensor nuclear factor erythroid 2-related factor 2 (NRF2) and provides glutathione building blocks by importing cystine [35, 36].”
BackgroundSelf-citationHydrogen peroxide toxicity on auditory cells: An in vitro study
Gentilin, E., Cani, A., Simoni, E., Chicca, M. C., Paolo, M. L. D., Martini, A., & Astolfi, L. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109575 · Cited by 20
Golgi apparatus targeted therapy in cancer: Are we there yet?
Lee, Z. Y., Lee, W. H., Lim, J. S., Ali, A. A. A., Loo, J. S. E., Wibowo, A., Mohammat, M. F., & Foo, J. B. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122868 · Cited by 19
The Janus Face of p53-Targeting Ubiquitin Ligases
Hao, Q., Chen, Y., & Zhou, X. Y. (2020) · Cells · doi:10.3390/cells9071656 · Cited by 16
“In addition, p53 can transcriptionally induce the expression of antioxidant genes, such as GPX1, GLS2, and TIGAR, which remove the excessive reactive oxygen species, thereby protecting the genome from the oxidative insult [5].”
BackgroundNazari, A., Osati, P., Fakhr, S. S., Faghihkhorasani, F., Ghanaatian, M., Faghihkhorasani, F., Rezaei‐Tazangi, F., Far, N. P., Shourideh, A., Ebrahimi, N., et al. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0491 · Cited by 21
Thakor, P., Siddiqui, M. Q., & Patel, T. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35158 · Cited by 12
“It also helps to maintain intracellular redox balance and genetic stability [92]. p53 is also a frequently altered gene in various malignancies and controls the PPP by binding directly to G6PD and inhibiting dimerization [93].”
BackgroundSodium Butyrate: A Multifaceted Modulator in Colorectal Cancer Therapy
Mederle, A. L., Semenescu, A.-D., Drăghici, G. A., Dehelean, C. A., VLĂDUT, N.-V., & Nica, D. V. (2025) · Medicina · doi:10.3390/medicina61010136 · Cited by 21
Dobre, M., Boscencu, R., Neagoe, I. V., Surcel, M., Milanesi, E., & Manda, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071032 · Cited by 12
Luo, G., Kumar, H., Aldridge, K., Rieger, S., Han, E., Jiang, E., Chan, E. R., Soliman, A., Mahdi, H., & Letterio, J. J. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0409 · Cited by 16
“Even NQO1 may not be the best representative of NRF2 activity in all cases as TP53 may play a role in its speci fi c expression (Beinse et al., 2019; Eriksson et al., 2019).”
Mitochondrial genome-derived circRNAs: Orphan epigenetic regulators in molecular biology
Sanadgol, N., Amini, J., Khalseh, R., Bakhshi, M., Nikbin, A., Beyer, C., & Zendehdel, A. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101968 · Cited by 9
D’Orazi, G., Garufi, A., & Cirone, M. (2020) · IUBMB Life · doi:10.1002/iub.2334 · Cited by 11
Arafa, A. T., Yadav, S., Marshall, C. H., Mauer, E. A., Huang, M., Yilma, B., van der Pol, Y., Fragkogianni, S., Teslow, E. A., Kellen, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2058 · Cited by 9
Wittke, C. I., Cheung, E. C., Athineos, D., Clements, N., Butler, L., Hughes, M., Morrison, V., Watt, D. M., Blyth, K., Vousden, K. H., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101397 · Cited by 9
“25 TIGAR is a fructose-2,6-bisphosphatase that acts in this capacity to limit accumulation of fructose-2,6-bisphosphate, a potent allosteric activator of phosphofructokinase-1.”
Ischemia-Reperfusion Injury: Molecular Mechanisms of Pathogenesis and Methods of Their Correction
Goncharov, R. G., & Sharapov, M. G. (2023) · Molecular Biology · doi:10.31857/s0026898423060071 · Cited by 18
Tonoi, T., Ikeda, M., Sato, T., Inohana, T., Kawahara, R., Murata, T., & Shiina, I. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202000459 · Cited by 8
Humpton, T. J., Hock, A. K., Kiourtis, C., Donatis, M. D., Fercoq, F., Nixon, C., Bryson, S., Strathdee, D., Carlin, L. M., Bird, T. G., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abd9099 · Cited by 10
“Ionizing radiation causes DNA damage and increased cellular reactive oxygen species (ROS) 41 , and p53 has been shown to contribute to both DNA repair and ROS control 42,43 .”
Effect of Peroxiredoxin 6 on p53 Transcription Factor Level
Sharapov, M. G., Goncharov, R. G., Parfenyuk, S. B., & Glushkova, O. V. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922080156 · Cited by 8
“Three of them (Cys176, Cys238, and Cys242) are bound to the zinc atom (together with His179) and play a vital role in the correct folding and functioning of p53 [18].”
BackgroundResultROS, Redox Regulation, and Anticancer Therapy
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 15
The Role of Peptidyl Arginine Deiminase IV(PADI4) in Cancers
Wang, W., Wu, X., & Wang, Y. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220614115309 · Cited by 7
Arkan, C., & Yildiz, D. A. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2422843 · Cited by 8
“Upon stabilization, Nrf2 translocates to the nucleus and controls the expression of genes involved in antioxidant system [31].”
Checa, J., Martínez-González, I., Maqueda, M., Mosquera, J. L., & Aran, J. M. (2021) · Antioxidants · doi:10.3390/antiox10121936 · Cited by 8
“2%) were associated to oxidative stress: CFLAR (CASP8 and FADD-like apoptosis regulator) [39]; PCNA (proliferating cell nuclear antigen, activated by ROS [40], which plays a fundamental role in the regulation of oxidative stress) [41,42]; MDM2, and the tumor suppressor TP53 (p53).”
BackgroundIntrinsic Disorder and Other Malleable Arsenals of Evolved Protein Multifunctionality
Aftab, A., Sil, S., Nath, S., Basu, A., & Basu, S. (2024) · Journal of Molecular Evolution · doi:10.1007/s00239-024-10196-7 · Cited by 9
“Hub proteins, due to their strategic high-degree multifunctional importance, constitute an important component in drug design (Fu et al. 2015; Eriksson et al. 2019).”
UGP2, a novel target gene of TP53, inhibits endothelial cells apoptosis and atherosclerosis
Zhang, R., He, X., Chen, J.-J., Wu, C.-M., Lin, Y., Wang, Y., Wang, Q., Zheng, L., & Hu, X. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123393 · Cited by 6
The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer
Punziano, C., Trombetti, S., Grosso, M., Tornesello, M. L., & Faraonio, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146588 · Cited by 6
“The thiore-doxin/thioredoxin reductase (Trx/TrxR) system serves to recycle a variety of proteins [163], like peroxiredoxins, ribonucleotide reductase as well as transcription factors, including p53 [234].”
Silwal, A., Reese, B., Patel, B. B., Li, Y., Kolev, M. V., La-Beck, N. M., Karbowniczek, M., & Markiewski, M. M. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400212 · Cited by 5
Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes
Jan, Y.-H., Heck, D. E., An, Y., Laskin, D. L., & Laskin, J. D. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00420 · Cited by 6
Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile
Brown, K., Jenkins, L. M. M., Crooks, D. R., Surman, D. R., Mazur, S. J., Xu, Y., Arimilli, B. S., Yang, Y., Lane, A. N., Fan, T. W. ‐., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1094210 · Cited by 5
“Thus, targeting mutant p53-containing tumors could represent a new mechanism to inhibit tumors by targeting cellular metabolism (83, 84) and use of p53”
Li, Y., Chen, B., Lin, X.-Y., Zhang, G.-C., Lai, J., Li, C., Lin, J., Guo, L., Xiao, W., Mok, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830124 · Cited by 5
“[median, range] 65 [5-95] 70 [10-95] 50 [5-90]”
Zhang, K., Zhou, L., Zhang, T., Fan, Z., Xie, M., Ding, Y., & Li, H. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.129121 · Cited by 5
p53: updates on mechanisms, biology and therapy (I)
Lane, D. P., & Verma, C. S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz017 · Cited by 5
Shadfar, S., Farzana, F., Saravanabavan, S., Rozario, A. M., Vidal, M., Jagaraj, C. J., Parakh, S., Parić, E., Yuan, K. C., Brocardo, M. G., et al. (2025) · Aging Cell · doi:10.1111/acel.70079 · Cited by 5
“Similarly, p53 is a well-characterised DDR protein and “guardian of the genome” (Feroz and Sheikh 2020) that also functions in redox homeostasis (Eriksson et al. 2019).”
Moore, L. L., Jaboin, J. J., Brown, M. L., & Houchen, C. W. (2025) · Cancers · doi:10.3390/cancers17122050 · Cited by 4
Wang, D., Zou, S., Ding, J., Gao, C., Wang, J., & Tang, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665056 · Cited by 8
Liu, C., & Zhang, A. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03967-8 · Cited by 4
“…is related to biphasic regulation of Nrf2, that is, p53 upregulated the Nrf2 protein level and its target antioxidant genes, protecting macromolecules from ROS-induced damage to promote cell survival, but under high level of p53, the Nrf2-mediated antioxidant response is inhibited by p53 [33, 34].”
Naeimzadeh, Y., Tajbakhsh, A., & Fallahi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26260 · Cited by 5
“Furthermore, several studies were indicated that the formation of mutated p53 aggregations is related to the loss of function (LOF), dominant-negative (DN), and GOF mutations at the hot spots of the amino acid sequence of this protein [13,37,39].”
BackgroundWen, C., Huang, C., Liao, X., Luo, Z., & Huang, C. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110047 · Cited by 4
Li, Z., Meng, C., Shen, G., Shan, Y., Wang, J., Abudukeremu, D., Zhao, R., Ni, B., Xu, C., Guo, X., et al. (2026) · Advanced Science · doi:10.1002/advs.202507346 · Cited by 6
“…in cancer cells with mutant TP53 include upregulation of the ROS scavenging system via NRF2 and activation of anti-apoptotic signaling via NF-κ B [ 47 ]; KRAS mutations promote aspartate biosynthesis by upregulating ATF4 and PI3K-AKT signaling to sustain tumor survival under oxidative stress [ 48…”
Autophagy–Apoptosis Crosstalk in Cancer: Mechanisms, Signaling Pathways, and Therapeutic Targeting
Kakkar, D., Saxena, S., Dhawan, U., Dosi, N., Khanna, C., & Paul, S. (2026) · Cancers · doi:10.3390/cancers18101564 · Cited by 4
ZHANG, X.-H., & Le, L. I. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2022-0009 · Cited by 3
G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung CancerPreprint
Lan, T., Arastu, S., Wang, S., Lam, J., Wang, W., Bhatt, V. D., Lopes, E. C., Hu, Z. S., Sun, M. T., Luo, X., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.06.561131 · Cited by 3
“…but while ROS are pro-tumorigenic, high ROS levels are cytotoxic 27 and can be induced by oncogenic activity 35 . p53 influences the cellular redox balance by regulating several genes with antioxidant or pro-oxidant properties, which depends on various factors, including p53 protein levels 36 .”
BackgroundTargeting P53 Gene in Breast Cancer
Abuhagr, A. M., Musa, E. B., Attir, O. A., & Alati, R. M. O. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is7.2746 · Cited by 3
Metadata
- Authors
- Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Wiman, Klas G
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-14
- Volume
- 11
- Issue
- 4
- Pages
- 330-341
- ISSN
- 1674-2788 (ISSN-L)
- 1759-4685
- PMC
- PMC6734141
- OpenAlex
- W2911745809
- Cited by
- 123
- References
- 132
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 19 · 2023: 18 · 2022: 15 · 2021: 20 · 2020: 13 · 2019: 8
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Molecular Cell Biology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Swedish Medical Research Council
- Swedish Cancer Fund
- Swedish Childhood Cancer Fund
- Radiumhemmets Forskningsfonder
- Knut & Alice Wallenberg Foundation
- European Research Council
- Aprea Therapeutics AB
- Karolinska Institutet
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Keywords
- TP53, p53, cellular redox homeostasis, TP53 mutation, missense mutations, Nrf2, TIGAR, GLS2, zinc binding, glutathione, cancer therapy, transcriptional regulation
- MeSH terms
- Antioxidants, DNA, Humans, Neoplasms, Sulfhydryl Compounds, Tumor Suppressor Protein p53, Oxidative Stress, Mutation, Missense, Small Molecule Libraries, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.